You are using an unsupported browser.
Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

Banner image with blue and red molecule

Congresses and Publications

Congress Materials

Access English-language abstracts, posters, and presentations presented at the following congresses

September 2022

Hematology Society of Australia and New Zealand (Blood)

Hematology Society of Australia and New Zealand (Blood)

September 2022 (Sydney, Australia)

Presentations

A phase 1 study with the novel BCL2 inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory CLL/SLL Preliminary safety and efficacy of BGB-11417, a potent and selective B-cell lymphoma 2 (BCL2) inhibitor, in patients with AML SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab in patients with treatment-naive CLL/SLL

Posters

ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib vs ibrutinib in patients with Waldenström macroglobulinemia Population-wide patterns of care in CLL in Australia: an analysis of the pharmaceutical benefits scheme data set Population-wide patterns of care in mantle cell lymphoma in Australia: an analysis of the pharmaceutical benefits scheme data set

Abstracts

A phase 1 study with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib vs ibrutinib in patients with Waldenström macroglobulinemia (WM) First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) Population-wide patterns of care in chronic lymphocytic leukemia (CLL) in Australia: an analysis of the pharmaceutical benefits scheme (PBS) dataset Population-wide patterns of care in mantle cell lymphoma (MCL) in Australia: an analysis of the pharmaceutical benefits scheme (PBS) dataset Preliminary safety and efficacy of BGB-11417, a potent and selective B-cell lymphoma 2 (BCL2) inhibitor, in patients with acute myeloid leukemia (AML) SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab (BR) in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
September 2022

European Society for Medical Oncology (ESMO)

European Society for Medical Oncology (ESMO)

September 2022 (Paris, France)

Presentations

Final analysis of RATIONALE-301: randomized, phase 3 study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma

Posters

AdvanTIG-105: phase 1b dose-expansion study of ociperlimab + tislelizumab with chemotherapy in patients with metastatic squamous and nonsquamous non-small cell lung cancer AdvanTIG-205: phase 2 trial of ociperlimab plus tislelizumab plus chemotherapy in first-line treatment of patients with locally advanced, unresectable, or metastatic non-small cell lung cancer DKN-01 and tislelizumab + chemotherapy as first-line (1L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial SAFFRON-301: a phase 3 study of tislelizumab with sitravatinib versus chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer previously treated with platinum-based chemotherapy and an anti-PD-1/PD-L1 antibody Tislelizumab versus docetaxel as second- or third-line therapy in previously treated patients with advanced non-small cell lung cancer (NSCLC): Asian and non-Asian subgroup analysis of the RATIONALE-303 study

Abstracts

AdvanTIG-105: phase 1b dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with metastatic squamous (sq) and non-squamous (non-sq) non-small cell lung cancer (NSCLC) AdvanTIG-205: phase 2 trial of ociperlimab (OCI) + tislelizumab (TIS) + chemotherapy (chemo) in first line (1L) treatment of patients (pts) with locally advanced (LA), unresectable, or metastatic non-small cell lung cancer (mNSCLC) Final analysis of RATIONALE-301: randomized, phase 3 study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma Phase 3 study of tislelizumab (TIS) with sitravatinib versus chemotherapy (chemo) in patients with locally advanced/metastatic non-small cell lung cancer (NSCLC) previously treated with chemo and an anti-programmed cell death protein 1/ligand 1 (PD-[L]1) antibody Tislelizumab (TIS) versus docetaxel (TAX) as second- or third-line therapy in previously treated patients (pts) with locally advanced non-small cell lung cancer (NSCLC): Asian versus non-Asian subgroup analysis of the RATIONALE-303 study
September 2022

Polish Society of Hematology and Transfusion Medicine (PTHiT)

Polish Society of Hematology and Transfusion Medicine (PTHiT)

September 2022 (Bydgoszcz, Poland)

Presentations

First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab in patients with treatment-naive CLL/SLL

Abstracts

First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab (BR) in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
September 2022

Korean Society of Medical Oncology (KSMO)

Korean Society of Medical Oncology (KSMO)

September 2022 (Seoul, South Korea)

Presentations

HERIZON-GEA-01: a phase 3 study of zanidatamab in combination with chemotherapy with or without tislelizumab in first-line human epidermal growth factor receptor 2 positive (HER2+) advanced/metastatic gastroesophageal adenocarcinoma (GEA) Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup

Posters

AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab in patients with metastatic NSCLC

Abstracts

AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab in patients with metastatic NSCLC HERIZON-GEA-01: phase 3 study of zanidatamab (ZANI) + chemotherapy (chemo) ± tislelizumab (TIS) in first-line (1L) human epidermal growth factor receptor 2 positive (HER2+) locally advanced (LA)/metastatic gastroesophageal adenocarcinoma (GEA) Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup
August 2022

World Congress on Lung Cancer (WCLC)

World Congress on Lung Cancer (WCLC)

August 2022 (Vienna, Austria)

Posters

AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab in patients with metastatic NSCLC Safety and efficacy of sitravatinib plus tislelizumab in patients with PD-L1-positive, locally advanced or metastatic, nonsquamous non-small cell lung cancer; SAFFRON-103 Safety and efficacy of sitravatinib plus tislelizumab in patients with PD-L1-positive, locally advanced or metastatic, squamous non-small cell lung cancer; SAFFRON-103 Tislelizumab versus docetaxel in previously treated advanced non-small cell lung cancer (NSCLC): final analysis of RATIONALE-303

Abstracts

AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab in patients with metastatic NSCLC Safety and efficacy of sitravatinib + tislelizumab in patients with PD-L1+, locally advanced/metastatic, non-squamous NSCLC Safety and efficacy of sitravatinib + tislelizumab in patients with PD-L1+, locally advanced/metastatic, squamous NSCLC Tislelizumab versus docetaxel in previously treated advanced non-small cell lung cancer: final analysis of RATIONALE-303
July 2022

Pan Pacific Lymphoma Conference (PPLC)

Pan Pacific Lymphoma Conference (PPLC)

July 2022 (Kauai, Hawaii)

Posters

ASPEN: long‑term follow‑up results of a phase 3 randomized trial of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma Zanubrutinib in 13 acalabrutinib‑intolerant patients with B‑Cell malignancies

Abstracts

ASPEN: long‑term follow‑up results of a phase 3 randomized trial of zanubrutinib (ZANU) vs ibrutinib (IBR) in patients with Waldenström macroglobulinemia (WM) SEQUOIA: results of a phase 3 randomized study of zanubrutinib (ZANU) versus bendamustine + rituximab (BR) in patients (pts) with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) Zanubrutinib in 13 acalabrutinib‑intolerant patients (pts) with B‑cell malignancies
See Full List of Congresses

Most Recent Publications

Banner image with blue and red molecule Your ability to access these articles may depend on your or your institution's subscriptions to the journals.

See full list of publications

Search Publications and Congress Materials

This website houses a database of publications and congress materials from medical congresses around the world. Use our search engine below to access information pertinent to your search needs.

Clear All

Publications

Banner image with blue and red molecule Your ability to access these articles may depend on your or your institution's subscriptions to the journals.

Publication Name
Author
Year
Disease State
Molecule
Loading publications, please wait... No publications found.
Showing [[ publicationsDisplayCount ]] of [[ publications.length ]]

Congresses

Material Type and Title
Congress
Year
Disease State
Molecule
Loading congresses, please wait... No congresses found.
Showing [[ countVisibleCongressDocs ]] of [[ congressDocuments.length ]]

BeiGene, Ltd. maintains the site for your personal information, education, and communication. Please feel free to browse the site. You may not, however, distribute, modify, transmit, reuse, repost or use the content of the site for public or commercial purposes, including the text and images, without BeiGene’s written permission.  
 
This is an online medical resource for scientific and clinical information. BeiGene makes no representation that the information in this site is appropriate for every country or region. If you choose to access this site, you are responsible for compliance with applicable local laws.